Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the closing of the recent trading day, Amgen (AMGN) stood at $297.32, denoting a +1.18% move from the preceding trading day.
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) reached $294.12 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.
The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.